secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beta Bionics, Inc. (BBNX)
CIK:        0001674632
Form:       8-K
Filed at:   2026-02-17T23:59:59+00:00
Accession:  0001171843-26-000859
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beta Bionics Q4 2025 revenue $32.1M (+57% YoY); guides FY2026 $130-135M
-----------------------------------------------------------------------

- Net sales $32.1M in Q4 (+57% YoY); full year $100.3M (+54%). Installed base 35,011 users (+129%).
- Gross margin 59% Q4 (up 179bps); FY gross margin 55.4%. Net loss $13.5M Q4 (improved from $18.1M).
- 2026 guidance: revenue $130M-$135M; PBP channel 36-38% of new starts; gross margin 55.5%-57.5%.
- Bihormonal system Phase 2a first-in-human trial completed in New Zealand; additional Phase 2a expected H1 2026.
- Cash $264.7M as of Dec 31, 2025. New patient starts up 37% Q4 to 5,592.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674632/000117184326000859/0001171843-26-000859-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674632/000117184326000859/f8k_021326.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-000859

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer